2022
Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report
Rotllan N, Zhang X, Canfrán-Duque A, Goedeke L, Griñán R, Ramírez CM, Suárez Y, Fernández-Hernando C. Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report. Biomedicine & Pharmacotherapy 2022, 153: 113419. PMID: 36076541, PMCID: PMC11140622, DOI: 10.1016/j.biopha.2022.113419.Peer-Reviewed Original ResearchConceptsProgression of atherosclerosisMiR-148aLipoprotein cholesterolAtherosclerotic lesionsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolAnti-inflammatory effectsAnti-inflammatory genesMacrophage cholesterol effluxWestern-style dietMiR-148a levelsHepatic gene expressionMurine primary macrophagesAntiatherogenic effectsAtherosclerosis progressionInflammatory responseTherapeutic silencingLipoprotein metabolismPlaque stabilityCholesterol effluxPrimary macrophagesPlaque sizeCholesterol homeostasisLesionsMRNA levels
2016
Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice
Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M, Perrotta P, Yin X, Bauer A, Leslie KL, Zhang P, Aryal B, Montgomery RL, Thum T, Martin K, Suarez Y, Mayr M, Fernandez-Hernando C, Sessa WC. Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Molecular Medicine 2016, 8: 643-653. PMID: 27137489, PMCID: PMC4888854, DOI: 10.15252/emmm.201506031.Peer-Reviewed Original ResearchConceptsPlaque morphologyReduced lesion sizeAcute myocardial infarctionAtherosclerotic mouse modelVulnerable atherosclerotic lesionsFibrous cap thicknessPlaque extracellular matrixChronic administrationExtracellular matrixAtherosclerotic miceMyocardial infarctionPlaque remodelingSolid organsAbnormal remodelingMouse modelAtherosclerotic lesionsAtherosclerotic plaquesBlood chemistryLesion sizeMiR-29Necrotic zoneLesionsPlaquesCap thicknessMiR-29 target genes